Paras Biopharmaceuticals Finland Oy

PB (MDT)-3010 (Diabetes)

Product Status:

• SDS-PAGE high Expressions
• Mass spectrometry: Confirmation of N-& C-Terminal, and AA sequence

Technology Status

• Soon to be available for licensing within scale-up production
• Recombinant state E. Coli / S. cerevisae clone exhibits expressions of the metabolic disorder treatment (PB (MDT)-3010) (EM@39000 -Paras Rights Reserved)
• SDA-PAGE-Gel image showing marker (lane 1), homogenization broth (lane 2) and separation of metabolic disorder treatment product (lane 3)
• Multiple batches carried out at small & large scales
• Processes optimized at scale-up level
• Biocomparability methods established
• Extensive product characterization done
• Biosimilarity established